The Concept of CMR

Intra-abdominal Adipose Tissue: the Culprit?

Atherogenic Dyslipidemia

References

Page: Go to Previous Page 15 of 15 Go to Next Page
  1. Genest J. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis 2003; 26: 267-87.
  2. Grundy SM. Cholesterol and Atherosclerosis, Diagnosis and Treatment. New York. Gower Medical Publishing. 1990.
  3. Havel RJ and Kane JP. Structure and metabolism of plasma lipoproteins; the metabolic and molecular bases of inherited disease. New York. McGraw-Hill. 1995.
  4. Ridker P, Genest J and Libby P. Plasma lipids and lipoproteins and cardiovascular diseases. Braunwald's Heart Disease. New-York. Saunders. 2000.
  5. Shelness GS and Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001; 12: 151-7.
  6. Olivecrona T, Hultin M, Bergo M, et al. Lipoprotein lipase: regulation and role in lipoprotein metabolism. Proc Nutr Soc 1997; 56: 723-9.
  7. Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
  8. Lamarche B and Paradis ME. Endothelial lipase and the metabolic syndrome. Curr Opin Lipidol 2007; 18: 298-303.
  9. Schaefer EJ and Asztalos BF. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 2006; 17: 394-8.
  10. Hussain MM, Fatma S, Pan X, et al. Intestinal lipoprotein assembly. Curr Opin Lipidol 2005; 16: 281-5.
  11. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
  12. Taskinen MR. Type 2 diabetes as a lipid disorder. Curr Mol Med 2005; 5: 297-308.
  13. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347-56.
  14. Després JP, Lemieux I, Tchernof A, et al. [Fat distribution and metabolism]. Diabetes Metab 2001; 27: 209-14.
  15. Després JP. Health consequences of visceral obesity. Ann Med 2001; 33: 534-41.
  16. Després JP. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest 2006; 29: 77-82.
  17. Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
  18. Després JP and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
  19. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006; 8 Suppl 1: S21-7.
  20. Lemieux S. Contribution of visceral obesity to the insulin resistance syndrome. Can J Appl Physiol 2001; 26: 273-90.
  21. Pouliot MC, Després JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41: 826-34.
  22. Després JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
  23. Pascot A, Lemieux I, Prud'homme D, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007-14.
  24. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-61.
  25. Frayn KN, Arner P and Yki-Jarvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem 2006; 42: 89-103.
  26. Ruotolo G and Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500.
  27. Mlinar B, Marc J, Janez A, et al. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007; 375: 20-35.
  28. Duez H, Lamarche B, Uffelman KD, et al. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26: 1357-63.
  29. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-9.
  30. Martins IJ and Redgrave TG. Obesity and post-prandial lipid metabolism. Feast or famine? J Nutr Biochem 2004; 15: 130-41.
  31. Botham KM, Bravo E, Elliott J, et al. Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development. Curr Pharm Des 2005; 11: 3681-95.
  32. Yuan G, Al-Shali KZ and Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113-20.
  33. Rizzo M and Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007; 23: 14-20.
  34. Forrester JS and Shah PK. Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 2006; 98: 1542-9.
Page: Go to Previous Page 15 of 15 Go to Next Page
Print this document